Company performance
Current Price
as of Feb 17, 2025$17.41
P/E Ratio
181.50
Market Cap
$5.78B
Description
Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.
Metrics
Overview
- HQMelbourne, VI
- SectorHealth Technology
- IndustryBiotechnology
- TickerTLX
- Price$17.405948+1.46%
Trading Information
- Market cap$5.78B
- Float75.14%
- Average Daily Volume (1m)1,203,777
- Average Daily Volume (3m)1,157,843
- EPS$0.02
Company
- Revenue$502.55M
- Rev growth (1yr)N/A
- Net income$17.97M
- Gross margin66.01%
- EBITDA margin18.48%
- EBITDA$32.34M
- EV$4.17B
- EV/Revenue8.30
- P/E181.50
- P/S14.37
- P/B22.64
- Debt/Equity10.53